Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.
Countdown to Humana (HUM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Humana (HUM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for
Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Soars 3.1%: Is Further Upside Left in the Stock?
Humana (HUM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?
Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here's Why it is Prudent for Investors to Hold Humana Stock for Now
HUM remains well-poised for growth, attributable to improved premiums, contract wins, acquisitions, collaborations and growing cash reserves.
Should Value Investors Buy Humana (HUM) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana, Cigna Plunge On Trump's Latest Promise: A Potential Buying Opportunity?
The healthcare industry, particularly PBMs, faces bipartisan scrutiny, leading to significant stock declines for Humana and Cigna, presenting a contrarian investment opportunity. President-elect Donald Trump's stance on PBMs and bipartisan legislative proposals signal potential regulatory changes, creating market uncertainty for PBM-affiliated companies. Despite recent financial setbacks, Cigna and Humana show strong revenue growth, with investment losses and rising benefit costs impacting short-term profitability.
Humana: Medicare Advantage Is Just A Short-Term Problem
Humana's stock has declined 18% while the S&P 500 returned 13.5%, driven by short-term issues with Medicare Advantage. Despite short-term cost challenges, Medicare Advantage remains a long-term tailwind, and CenterWell coordinated care isn't priced into Humana's strategy. I maintain buy rating at a price target of $370, 28% upside.
Humana says Susan Diamond to step down as CFO
Humana Inc said on Tuesday that Chief Financial Officer Susan Diamond was stepping down and Celeste Mellet would replace her, effective Jan. 11.
Humana (HUM) Up 15.1% Since Last Earnings Report: Can It Continue?
Humana (HUM) reported earnings 30 days ago. What's next for the stock?
